Delta-9-Tetrahydrocannabinol (∆9-THC) and Cannabidiol (CBD) Drug-Drug Interactions

Although prescribing information is often the initial source of information when identifying potential drug-drug interactions, it may only provide a limited number of exemplars or only reference a class of medications without providing any specific medication examples. In the case of medical cannabis and medicinal cannabinoids, this is further complicated by the fact that the increased therapeutic use of marijuana extracts and CBD oil will not have regulatory agency approved prescribing information. The objective of these datasets is to provide a detailed and comprehensive drug-drug interaction list that is aligned with cannabinoid manufacturer prescribing information. The cannabinoid drug-drug interaction information is listed as a PRECIPITANT (cannabinoid) medication that either INHIBITS/INDUCES the metabolism or competes for the same SUBSTRATE target (metabolic enzyme) of an OBJECT (OTHER) medication. In addition to a comprehensive list of drug-drug interactions, we also provide a list of 57 prescription medications displaying a narrow therapeutic index that are potentially impacted by concomitant cannabinoid use (whether through prescription use of cannabinoid medications or therapeutic/recreational use of cannabis and its extracts). This peer reviewed journal article has been published online with the following citation Med Cannabis Cannabinoids (DOI:10.1159/000507998)



Work Title Delta-9-Tetrahydrocannabinol (∆9-THC) and Cannabidiol (CBD) Drug-Drug Interactions
Open Access
  1. Paul T. Kocis, PharmD, MPH
  2. Kent E. Vrana, PhD
  1. cytochrome P450
  2. safety
  3. medical marijuana
  4. cannabidiol
  5. cannabis
  6. drug-drug interactions
  7. CBD
  8. metabolism
  9. THC
  10. delta-9-tetrahydrocannabidiol
License CC BY-NC-ND 4.0 (Attribution-NonCommercial-NoDerivatives)
Work Type Dataset
Publication Date July 12, 2023
DOI doi:10.26207/1t9z-ep92
Deposited June 08, 2020




This resource is currently not in any collection.

Work History

Version 1

  • Created
  • Added Delta-9-THC_and_Cannabidiol_DDI_-_Table_2_-_attributed_Kocis-Vrana_2020_doi_10.1159000507998_2020_08_17.pdf
  • Added NTI_Meds_to_be_Closely_Monitored_when_Co-Administered_with_Cannabinoids_2020_04_25.pdf
  • Added Suppl_B_-_Kocis___Vrana_COM_SUPPL_MATERIAL-B___DATA___2020_03_15___DATA_updtd_04_13_SHEET_updtd_04_25_Legend_PP.xlsx
  • Added Creator Paul T. Kocis, PharmD, MPH
  • Added Creator Kent E. Vrana, PhD
  • Published

Version 2

  • Created
  • Updated
  • Deleted Suppl_B_-_Kocis___Vrana_COM_SUPPL_MATERIAL-B___DATA___2020_03_15___DATA_updtd_04_13_SHEET_updtd_04_25_Legend_PP.xlsx
  • Deleted NTI_Meds_to_be_Closely_Monitored_when_Co-Administered_with_Cannabinoids_2020_04_25.pdf
  • Updated Publication Date Show Changes
    Publication Date
    • 2023-07-12
  • Published